IP CONTROL ADMISSION SYSTEM

Access Is Earned. Formula Security Is Enforced.

Olympia Biosciences™ is not an open manufacturing pipeline. We admit only enterprise and medical mandates where legal control, ISO-audited data governance, and transfer discipline can be enforced from day zero.

MANDATORY ENTRY CONDITION

PAID DUE DILIGENCE

FILTER INTENSITY

LOW-INTENT MANDATES DECLINED

INITIATE R&D DUE DILIGENCE DATA ROOM / LEGAL HUB →

STRUCTURAL THREAT MODEL

Most Formula Losses Start With Incentive Failures, Not Hackers.

The highest-probability breach in supplement manufacturing is economic: a producer that can monetize adjacent formulas through private-label channels. Our architecture removes that conflict before technical work begins, then layers audited legal and data controls.

REJECTION CRITERIA

  • PRICE-FIRST PROCUREMENTS WITHOUT CLINICAL OR STRATEGIC THESIS
  • PRIVATE-LABEL REQUESTS DISGUISED AS INNOVATION MANDATES
  • TEAMS SEEKING FREE SCOPING OR SPECULATIVE QUOTING
  • PROGRAMS WITHOUT OWNER FOR REGULATORY AND CLAIM GOVERNANCE

ADMISSION TRIGGER

No Free Scoping. No Open Intake. No Commodity Pipeline.

The due diligence gate protects active partners from speculative demand and preserves team bandwidth for defensible mandates only.

ADMISSION REQUIREMENTS

BOARD SPONSOR WITH BUDGET AUTHORITY AND EXECUTION TIMELINE
DEFENSIBLE EBM OR TRANSFER THESIS WITH MEASURABLE MOAT TARGET
READINESS FOR ANALYTICAL RELEASE, PPQ DISCIPLINE, AND QA GOVERNANCE
COMMITMENT TO START WITH PAID DUE DILIGENCE
IP Security Control Matrix
CONTROL LAYER ENFORCEMENT STANDARD BOARD-LEVEL IMPACT
LEGAL ACCESS CONTROL NDA BEFORE TECHNICAL DISCLOSURE THESIS LEAKAGE BLOCKED BEFORE FIRST DATA EXCHANGE
DATA SEGMENTATION ISO 27001 ROLE-BASED ACCESS FORMULA FILES TRACEABLE, LOGGED, AND RESTRICTED
CONFLICT ELIMINATION ZERO CONSUMER BRAND OPERATIONS NO STRUCTURAL INCENTIVE TO CLONE CLIENT FORMULAS
IP TRANSFER FRAME FULL CLIENT OWNERSHIP TERMS DOSSIER BECOMES TRANSACTION-GRADE BALANCE-SHEET ASSET

SCROLL HORIZONTALLY TO REVIEW FULL CONTROL SURFACE

FINAL ADMISSION CHECK

If Your Mandate Is Defensible, Enter. If Not, We Decline.

Olympia Biosciences™ is built for enterprise operators, PE-backed teams, and medical leaders who treat formulation secrecy as valuation infrastructure.

INITIATE R&D DUE DILIGENCE DATA ROOM / LEGAL HUB →

Frequently Asked Questions

Why does Olympia enforce a paid admission gate before production scoping?
Because open intake destroys security architecture. The admission gate verifies mandate quality, ownership discipline, and governance readiness before any formulation intelligence is exposed.
What exactly is delivered in the R&D due diligence phase?
A go or no-go board package: threat map, transfer-risk framing, control-surface design, regulatory pressure points, and execution verdict. It is an operational decision framework, not a sales call.
How do you make formula leakage structurally improbable over long cooperation?
Through segmented access, immutable trace logs, role-bound data handling, and a no-consumer-brand operating model. Security is enforced by architecture and incentives, not declarations.
Who owns the final formulation intelligence and dossier outputs?
The client. Final specifications, release logic, and supporting documentation transfer under contractual IP ownership terms for enterprise continuity and valuation readiness.
Can private-label or low-MOQ projects bypass this gate?
No. This page is designed for high-governance mandates where IP control is mission-critical. Commodity inquiries are intentionally filtered out.
What strategic promise does this model guarantee to enterprise partners?
We do not monetize your idea twice. We secure, engineer, and transfer defensible formulation assets under audited controls.

RELATED INTELLIGENCE

Proprietary Encapsulation Technology Defensible trade secret formulations — liposomal and micellar systems EXPLORE › Production Formats & MOQ Reference Hard capsules 150K, softgels 300K, sachets 250K — your MOQ, your MBR, your formula protected under ISO 27001 EXPLORE › Physician Supplement Brand CDMO Zero conflict of interest — we never own consumer brands competing with yours EXPLORE › CDMO vs. Private Label: IP Ownership Comparison Why true CDMO matters for formula exclusivity and brand valuation EXPLORE › 10 Evidence-Based CDMO Security Advantages Quantified IP protection vs. standard contract manufacturers EXPLORE › Science-First Manifesto — The IP Trust Framework Our founding doctrine: your formulation data is your most valuable asset EXPLORE ›